Chronic morphine use for cancer pain may increase bone loss

Credit: Unsplash+

Opioids like morphine have long been the standard treatment for managing severe cancer-induced bone pain.

However, recent research has uncovered a concerning mechanism by which chronic morphine use may contribute to increased bone loss and pain.

This discovery sheds light on potential side effects associated with long-term opioid use in cancer patients.

Cancer-Induced Bone Pain

Bone metastasis, the spread of cancer to the bone, is a common occurrence in cancer patients.

According to the National Institutes of Health, it’s the most frequent site for metastatic cancer, particularly in cases of prostate, breast, and lung cancers.

One of the primary symptoms of bone metastasis is intense pain, which significantly impacts the quality of life for cancer patients.

A recent study published in the journal PAIN highlights the potential risks associated with chronic morphine use in cancer patients.

The study, led by senior author Todd Vanderah from the University of Arizona Health Sciences Comprehensive Pain and Addiction Center, reveals a mechanism by which morphine may contribute to increased bone loss and pain.

Understanding the Mechanism

The study focused on how morphine interacts with specific receptors in the body, particularly mu opioid receptors and toll-like receptor 4 (TLR4).

Mu opioid receptors are the primary targets for opioids and play a crucial role in pain management.

TLR4 receptors, on the other hand, are typically found on immune cells and are involved in recognizing and responding to foreign substances, such as cancer cells.

In both laboratory experiments and preclinical mouse models, the researchers observed that when morphine interacted with TLR4, it triggered a cellular cascade that led to increased inflammation.

Additionally, it resulted in elevated activity and production of osteoclasts, cells responsible for breaking down bone tissue. The consequence of this interaction was more significant bone loss and heightened pain levels.

Importantly, when TLR4 was blocked, there was no increase in pain or bone loss caused by morphine. This mechanism was not observed when the mu opioid receptor was tested.

Implications for Cancer Patients

The study’s findings suggest that chronic morphine use, while effective in managing pain, may have unintended consequences, such as increased bone loss and pain.

This doesn’t mean that opioids should be entirely removed from cancer treatment plans, but it emphasizes the need to explore alternative therapies that can mitigate the potential side effects of opioids.

Further research is necessary to gain a more comprehensive understanding of how opioids affect the body, not only at their known receptors but also at off-target sites.

This knowledge could help predict and address the challenges associated with the treatment of cancer-induced bone pain more effectively.

It may also lead to the development of improved treatments that minimize bone loss and pain for cancer patients.


Chronic pain remains a significant concern for cancer patients, especially those with bone metastasis. Opioids like morphine have been valuable in managing pain; however, this study reveals a potential downside to their use.

While opioids provide relief, they may also contribute to bone loss and increased pain levels.

This underscores the importance of ongoing research to find safer and more effective treatments for cancer-induced bone pain, ultimately improving the quality of life for patients battling this challenging condition.

If you care about pain, please read studies about how to manage your back pain, and Krill oil could improve muscle health in older people.

For more information about pain, please see recent studies about how to live pain-free with arthritis, and results showing common native American plants may help reduce diarrhea and pain.

The research findings can be found in the journal PAIN.

Follow us on Twitter for more articles about this topic.

Copyright © 2023 Knowridge Science Report. All rights reserved.